Publications 2025

Bregni G, Adams R, Bale R, Bali MA, Bargellini I, Blomqvist L, Brown G, Cremolini C, Demetter P, Denecke T, Dohan A, Dopazo C, Elez E, Evrard S, Feakins R, Guckenberger M, Guren MG, Hawkins M, Hoorens A, Huguet E, Intven M, Koessler T, Kunz WG, Lordick F, Lucidi V et al. (2025)
EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases
Cancer Treat Rev, 136, 102926
DOI 10.1016/j.ctrv.2025.102926, PubMed 40179590

Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, Wilmink H, Crede M, Koenig A, Koenig U, Liffers ST, Antweiler K, Uijterwijk B, Seppanen H, Nordin A, Puolakkainen P, Dajani OF, Labori KJ, Johansson M, Bratlie SO, Friede T, Jo P (2025)
Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
BMC Cancer, 25 (1), 208
DOI 10.1186/s12885-025-13573-7, PubMed 39915735

Kolstad A, Emanuel G, Hjortland GO, Nilssen Y, Ulvestad M, Areffard A, Aahlin EK (2025)
Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Acta Oncol, 64, 540-549
DOI 10.2340/1651-226X.2025.43167, PubMed 40235057

Leysen L, Marticic Giljevic K, Piccinin C, Shkodra M, Pe M, Petersen M, Apolone G, Brunelli C, Lombardo C, Velikova G, Gilbert A, Pravettoni G, Ciliberto G, Groenvold M, Ferrer M, Bos N, Pietrobon R, Couespel N, Caraceni A, Guren M, Sirven A, Vachon H, EUonQOL consortium (2025)
Evaluation of the psychometric properties of patient-reported outcome measures of health-related quality of life across the European cancer continuum: a systematic review protocol using COSMIN methodology
BMJ Open, 15 (3), e088716
DOI 10.1136/bmjopen-2024-088716, PubMed 40157731

Njølstad TH, Jensen K, Andersen HK, Berstad AE, Hagen G, Johansen CK, Øye K, Glittum J, Dybwad A, Thingstad E, Guren MG, Dormagen JB, Schulz A (2025)
Deep learning reconstruction for detection of liver lesions at standard-dose and reduced-dose abdominal CT
Eur Radiol (in press)
DOI 10.1007/s00330-025-11596-z, PubMed 40251443

Smedman TM, Line PD, Dueland S (2025)
Assessing the attitudes of next of kin toward living donor liver transplantation for patients with colorectal liver metastases
Scand J Surg, 14574969251335467 (in press)
DOI 10.1177/14574969251335467, PubMed 40271620

Yaqub S, Busund S, Smedman TM, Syversveen T, Khan A, Solheim JM, Folseraas T, Wiencke K, Lassen K, Dueland S, Line PD (2025)
Liver transplantation for locally advanced non-resectable intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: early results from the TESLA trial
Br J Surg, 112 (3)
DOI 10.1093/bjs/znaf054, PubMed 40099404

Yaqub S, Longva A, Angelsen JH, Brudvik KW, Carling U, Edwin B, Fretland ÅA, Grünhagen DJ, Line PD, Røsok BI, Smedman TM, Sparrelid E, Syversveen T, Villanger O, Lassen K (2025)
Multimodal treatment for colorectal liver metastases: A toolbox for clinicians
Scand J Surg, 14574969251333524 (in press)
DOI 10.1177/14574969251333524, PubMed 40247715

Publications 2024

Brown LR, Sousa MS, Yule MS, Baracos VE, McMillan DC, Arends J, Balstad TR, Bye A, Dajani O, Dolan RD, Fallon MT, Greil C, Hjermstad MJ, Jakobsen G, Maddocks M, McDonald J, Ottestad IO, Phillips I, Sayers J, Simpson MR, Vagnildhaug OM, Solheim TS, Laird BJA, Skipworth RJE, Cancer Cachexia Endpoints Working Group (2024)
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 15 (3), 816-852
DOI 10.1002/jcsm.13478, PubMed 38738581

Chávez-Villa M, Ruffolo LI, Byrne M, Line PD, Dueland S, Tomiyama K, Hernandez-Alejandro R (2024)
Reply to A. Jain et al
J Clin Oncol, 42 (26), 3165-3166
DOI 10.1200/JCO.24.00922, PubMed 38976818

Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe IMB, Hjortland GO, Myklebust TÅ, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Knappskog S, Sorbye H (2024)
Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms
Br J Cancer, 131 (4), 676-684
DOI 10.1038/s41416-024-02773-w, PubMed 38909137

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjærde OC, Tveit KM, Spindler KG, Pallisgaard N, Kure EH (2024)
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clin Colorectal Cancer (in press)
DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478

Hanekamp BA, Virdee PS, Goh V, Jones M, Hvass Hansen R, Hjorth Johannesen H, Schulz A, Serup-Hansen E, Guren MG, Muirhead R (2024)
Diffusion-weighted magnetic resonance imaging as an early prognostic marker of chemoradiotherapy response in squamous cell carcinoma of the anus: An individual patient data meta-analysis
Phys Imaging Radiat Oncol, 31, 100618
DOI 10.1016/j.phro.2024.100618, PubMed 39188809

Hjermstad MJ, Jakobsen G, Arends J, Balstad TR, Brown LR, Bye A, Coats AJS, Dajani OF, Dolan RD, Fallon MT, Greil C, Grzyb A, Kaasa S, Koteng LH, May AM, McDonald J, Ottestad I, Philips I, Roeland EJ, Sayers J, Simpson MR, Skipworth RJE, Solheim TS, Sousa MS, Vagnildhaug OM et al. (2024)
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 15 (3), 794-815
DOI 10.1002/jcsm.13453, PubMed 38553255

Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D et al. (2024)
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Lancet Gastroenterol Hepatol, 9 (3), 205-217
DOI 10.1016/S2468-1253(23)00405-3, PubMed 38237621

Labori KJ, Bratlie SO, Dueland S, Lassen K (2024)
NORPACT-1: implications for future trials - Authors' reply
Lancet Gastroenterol Hepatol, 9 (5), 408-409
DOI 10.1016/S2468-1253(24)00079-7, PubMed 38604194

Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B et al. (2024)
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
Ann Oncol, 36 (2), 197-207
DOI 10.1016/j.annonc.2024.10.829, PubMed 39542422

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM (2024)
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
Mol Ther, 32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964

Mala T, Abelseth BK, Al-Haidari G, Dørum LMR, Hatlevoll I, Rekstad LC, Stenvold H, Øvrebø KK, Aahlin EK (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (15)
DOI 10.4045/tidsskr.24.0547, PubMed 39692659

Nome RV, Flatebø Ø, Bøe SL, Klaasen RA, Aamdal E, Normann M, Bolstad N, Warren DJ (2024)
A simple automated assay format for measuring multiple immune checkpoint inhibitors
J Pharm Biomed Anal, 255, 116657
DOI 10.1016/j.jpba.2024.116657, PubMed 39756153

Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
Oncoimmunology, 13 (1), 2372886
DOI 10.1080/2162402X.2024.2372886, PubMed 38952672

Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
Br J Cancer, 130 (12), 1921-1928
DOI 10.1038/s41416-024-02696-6, PubMed 38664577

Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R, plus the CORMAC-2 collaborators (2024)
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set
EClinicalMedicine, 78, 102939
DOI 10.1016/j.eclinm.2024.102939, PubMed 39720423

Slørdahl KS, Balto A, Guren MG, Wibe A, Kørner H, Norderval S, Gjelsvik YM, Myklebust TÅ, Larsen IK (2024)
Patient-reported outcomes after treatment for rectal cancer-A prospective nationwide study
Colorectal Dis, 27 (1) (in press)
DOI 10.1111/codi.17231, PubMed 39515999

Sodergren SC, Hurley-Wallace A, Vassiliou V, Alkhaffaf B, Batsaikhan B, Darlington AS, Fleitas-Kanonnikof T, Guren MG, Honda M, Kim YW, Kim S, Krishnamurthy MN, Loh SY, Turhal NS, Zhou J, Dennis K, Krishnatry R, Terashima M, Tsironis G, Yoshikawa T, Terada M, EORTC Quality of Life Group (2024)
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
Gastric Cancer, 27 (4), 722-734
DOI 10.1007/s10120-024-01492-8, PubMed 38668819

Sorbye H, Hjortland GO, Vestermark LW, Sundlov A, Assmus J, Couvelard A, Perren A, Langer SW (2024)
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 36 (11), e13428
DOI 10.1111/jne.13428, PubMed 38937137

Urrizola A, Dajani O, Aass N, Bjerkeset E, Hjermstad MJ, Kaasa S, Klepstad P, Pirnat A, Raaness I, Steinsheim H, Bye A (2024)
Nutrition impact symptom monitoring and weight loss outcomes: a longitudinal radiotherapy study
BMJ Support Palliat Care (in press)
DOI 10.1136/spcare-2024-004939, PubMed 38862183

Westgaard A, Pirnat A, Hjermstad MJ, Aass N, Kaasa S, Dajani OF (2024)
Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers-Simple Tools Matter
Curr Oncol, 31 (9), 5462-5471
DOI 10.3390/curroncol31090404, PubMed 39330032

Willmann J, Balermpas P, Rimner A, Appelt AL, Vasquez Osorio EM, Rønde HS, Day M, Embring A, Gabryś D, Guren MG, Hoskin P, Massaccesi M, Mayo C, Murray L, Nieder C, Guckenberger M, Andratschke N (2024)
Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database
Radiother Oncol, 202, 110624
DOI 10.1016/j.radonc.2024.110624, PubMed 39532233

Publications 2023

Acosta Roa AM, Skingen VE, Rekstad BL, Undseth C, Rusten E, Hernes E, Guren MG, Malinen E (2023)
Stability of metabolic tumor volume may enable radiotherapy dose painting in anal cancer
Phys Med, 114, 103151
DOI 10.1016/j.ejmp.2023.103151, PubMed 37813051

Dueland S, Smedman TM, Syversveen T, Grut H, Hagness M, Line PD (2023)
Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial
JAMA Surg, 158 (9), e232932
DOI 10.1001/jamasurg.2023.2932, PubMed 37494056

Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, Lothe IMB, Sorbye H (2023)
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 35 (4), e13256
DOI 10.1111/jne.13256, PubMed 37017614

Farnes I, Kleive D, Verbeke CS, Aabakken L, Issa-Epe A, Småstuen MC, Fosby BV, Dueland S, Line PD, Labori KJ (2023)
Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2)
BJS Open, 7 (6)
DOI 10.1093/bjsopen/zrad137, PubMed 38155512

Hanekamp BA, Viktil E, Slørdahl KS, Dormagen JB, Kløw NE, Malinen E, Brunborg C, Guren MG, Schulz A (2023)
Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome
Strahlenther Onkol, 200 (1), 19-27
DOI 10.1007/s00066-023-02114-5, PubMed 37429949

Jenul A, Stokmo HL, Schrunner S, Hjortland GO, Revheim ME, Tomic O (2023)
Novel ensemble feature selection techniques applied to high-grade gastroenteropancreatic neuroendocrine neoplasms for the prediction of survival
Comput Methods Programs Biomed, 244, 107934
DOI 10.1016/j.cmpb.2023.107934, PubMed 38016391

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A (2023)
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
JCO Precis Oncol, 7, e2200336
DOI 10.1200/PO.22.00336, PubMed 36753687

Morken S, Langer SW, Sundlöv A, Vestermark LW, Ladekarl M, Hjortland GO, Svensson JB, Tabaksblat EM, Haslerud TM, Assmus J, Detlefsen S, Couvelard A, Perren A, Sorbye H (2023)
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Br J Cancer, 129 (12), 1930-1939
DOI 10.1038/s41416-023-02462-0, PubMed 37872405

Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M (2023)
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
Ann Oncol, 34 (11), 1015-1024
DOI 10.1016/j.annonc.2023.08.010, PubMed 37657554

Nilsson MP, Undseth C, Albertsson P, Eidem M, Havelund BM, Johannsson J, Johnsson A, Radu C, Serup-Hansen E, Spindler KL, Zakrisson B, Guren MG, Kronborg C (2023)
Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer
Acta Oncol, 62 (8), 897-906
DOI 10.1080/0284186X.2023.2240490, PubMed 37504978

Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C (2023)
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Eur J Nucl Med Mol Imaging, 50 (13), 4010-4023
DOI 10.1007/s00259-023-06320-2, PubMed 37632562

Rowsell A, Sodergren SC, Vassiliou V, Darlington AS, Guren MG, Alkhaffaf B, Moorbey C, Dennis K, Terada M (2023)
Correction to: Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 26 (1), 167
DOI 10.1007/s10120-022-01346-1, PubMed 36269499

Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Ladekarl M, Tabaksblat EM, Knappskog S (2023)
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 30 (10)
DOI 10.1530/ERC-23-0057, PubMed 37410378

Wehrle CJ, Fujiki M, Schlegel A, Whitsett Linganna M, Pita A, Kim JK, Kwon DCH, Miller C, Hashimoto K, Dueland S, Sasaki K, Sapisochin G, Line PD, Hernandez-Alejandro R, Aucejo F (2023)
Update to 'A Contemporary Systematic Review on Liver Transplantation for Unresectable Liver Metastasis of Colorectal Cancer'
Ann Surg Oncol, 31 (2), 697-700
DOI 10.1245/s10434-023-14611-z, PubMed 37996635

Publications 2022

Bahadoer RR, Bastiaannet E, Peeters KCMJ, van Eycken E, Verbeeck J, Guren MG, Kørner H, Martling A, Johansson R, van de Velde CJH, Dekker JWT (2022)
The survival gap between young and older patients after surgical resection for colorectal cancer remains largely based on early mortality: A EURECCA comparison of four European countries
J Geriatr Oncol, 13 (6), 803-812
DOI 10.1016/j.jgo.2022.04.011, PubMed 35527207

Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C (2022)
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
ESMO Open, 7 (5), 100589
DOI 10.1016/j.esmoop.2022.100589, PubMed 36183444

Dijkstra EA, Hospers GAP, Kranenbarg EM, Fleer J, Roodvoets AGH, Bahadoer RR, Guren MG, Tjalma JJJ, Putter H, Crolla RMPH, Hendriks MP, Capdevila J, Radu C, van de Velde CJH, Nilsson PJ, Glimelius B, van Etten B, Marijnen CAM (2022)
Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial
Radiother Oncol, 171, 69-76
DOI 10.1016/j.radonc.2022.04.013, PubMed 35447283

Dueland S, Smedman TM, Grut H, Syversveen T, Jørgensen LH, Line PD (2022)
PET-Uptake in Liver Metastases as Method to Predict Tumor Biological Behavior in Patients Transplanted for Colorectal Liver Metastases Developing Lung Recurrence
Cancers (Basel), 14 (20)
DOI 10.3390/cancers14205042, PubMed 36291826

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G (2022)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
J Transl Med, 20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Falk P, Severin M, Berglund Å, Guren MG, Hofsli E, Österlund P, Tandberg A, Eberhard J, Sorbye H (2022)
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Cancer Treat Res Commun, 31, 100517
DOI 10.1016/j.ctarc.2022.100517, PubMed 35114500

Franco P, Segelov E, Johnsson A, Riechelmann R, Guren MG, Das P, Rao S, Arnold D, Spindler KG, Deutsch E, Krengli M, Tombolini V, Sebag-Montefiore D, De Felice F (2022)
A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer
Cancers (Basel), 14 (7)
DOI 10.3390/cancers14071697, PubMed 35406469

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Kørner H, Guren MG, Larsen IK, Haugen DF, Søreide K, Kørner LR, Søreide JA (2022)
Characteristics and fate of patients with rectal cancer not entering a curative-intent treatment pathway: A complete nationwide registry cohort of 3,304 patients
Eur J Surg Oncol, 48 (8), 1831-1839
DOI 10.1016/j.ejso.2022.04.013, PubMed 35527055

Langen Stokmo H, Aly M, Bowitz Lothe IM, Borja AJ, Mehdizadeh Seraj S, Ghorpade R, Miao X, Hjortland GO, Malinen E, Sorbye H, Werner TJ, Alavi A, Revheim ME (2022)
Volumetric parameters from [¹⁸ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 34 (7), e13170
DOI 10.1111/jne.13170, PubMed 35729738

Lundeby T, Finset A, Kaasa S, Wester TE, Hjermstad MJ, Dajani O, Wist E, Aass N (2022)
A complex communication skills training program for physicians providing advanced cancer care - content development and barriers and solutions for implementation
J Commun Healthc, 16 (1), 46-57
DOI 10.1080/17538068.2022.2039468, PubMed 36919800

Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579

Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B (2022)
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226

Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A et al. (2022)
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial
Front Oncol, 12, 917961
DOI 10.3389/fonc.2022.917961, PubMed 35912196

Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J (2022)
Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery
Phys Imaging Radiat Oncol, 22, 1-7
DOI 10.1016/j.phro.2022.03.002, PubMed 35372704

Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP (2022)
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
ESMO Open, 7 (4), 100529
DOI 10.1016/j.esmoop.2022.100529, PubMed 35816951

Rowsell A, Sodergren SC, Vassiliou V, Darlington AS, Guren MG, Alkhaffaf B, Moorbey C, Dennis K, Terada M (2022)
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 25 (4), 665-677
DOI 10.1007/s10120-022-01309-6, PubMed 35689705

Segelov E, Guren MG, Sebag-Montefiore D, Rao S, Johnsson A, Franco P, Deutsch E, Arnold D, Spindler KG (2022)
"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC)
Clin Colorectal Cancer, 21 (3), 175-187
DOI 10.1016/j.clcc.2022.02.006, PubMed 35346604

Smedman TM, Guren TK, Tveit KM, Thomsen M, Andersen MH, Line PD, Dueland S (2022)
Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
Transpl Int, 35, 10404
DOI 10.3389/ti.2022.10404, PubMed 35707633

Sodergren SC, Johnson CD, Gilbert A, Darlington AS, Cocks K, Guren MG, Rivin Del Campo E, Brannan C, Christensen P, Chu W, Chung H, Dennis K, Desideri I, Gilbert DC, Glynne-Jones R, Jefford M, Johansson M, Johnsson A, Juul T, Kardamakis D, Lai-Kwon J, McFarlane V, Miguel IMC, Nugent K, Peters F et al. (2022)
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life Questionnaire
Int J Radiat Oncol Biol Phys, 115 (5), 1155-1164
DOI 10.1016/j.ijrobp.2022.11.002, PubMed 36402360

Solheim JM, Dueland S, Line PD, Hagness M (2022)
Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study
Ann Surg, 278 (2), 239-245
DOI 10.1097/SLA.0000000000005703, PubMed 36082986

Steinberg MF, Olsen JA, Persse D, Souders CM, Wik L (2022)
Efficacy of defibrillator pads placement during ventricular arrhythmias, a before and after analysis
Resuscitation, 174, 16-19
DOI 10.1016/j.resuscitation.2022.03.004, PubMed 35276312

Theophanous S, Lønne PI, Choudhury A, Berbee M, Dekker A, Dennis K, Dewdney A, Gambacorta MA, Gilbert A, Guren MG, Holloway L, Jadon R, Kochhar R, Mohamed AA, Muirhead R, Parés O, Raszewski L, Roy R, Scarsbrook A, Sebag-Montefiore D, Spezi E, Spindler KG, van Triest B, Vassiliou V, Malinen E et al. (2022)
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study
Diagn Progn Res, 6 (1), 14
DOI 10.1186/s41512-022-00128-8, PubMed 35922837

Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

Bahadoer RR, Bastiaannet E, Claassen YHM, van der Mark M, van Eycken E, Verbeeck J, Guren MG, Kørner H, Martling A, Johansson R, van de Velde CJH, Dekker JWT (2021)
One-year excess mortality and treatment in surgically treated patients with colorectal cancer: A EURECCA European comparison
Eur J Surg Oncol, 47 (7), 1651-1660
DOI 10.1016/j.ejso.2021.01.011, PubMed 33518367

Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, Välimäki K, Bjørnslett M, Guren MG, Kallioniemi O, Nesbakken A, Lothe RA, Pellinen T (2021)
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Mol Oncol, 16 (12), 2312-2329
DOI 10.1002/1878-0261.13159, PubMed 34890102

Choudhury A, Theophanous S, Lønne PI, Samuel R, Guren MG, Berbee M, Brown P, Lilley J, van Soest J, Dekker A, Gilbert A, Malinen E, Wee L, Appelt AL (2021)
Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study
Radiother Oncol, 159, 183-189
DOI 10.1016/j.radonc.2021.03.013, PubMed 33753156

Dueland S, Smedman TM, Røsok B, Grut H, Syversveen T, Jørgensen LH, Line PD (2021)
Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases
Transpl Int, 34 (11), 2205-2213
DOI 10.1111/tri.13995, PubMed 34792825

Groendahl AR, Moe YM, Kaushal CK, Huynh BN, Rusten E, Tomic O, Hernes E, Hanekamp B, Undseth C, Guren MG, Malinen E, Futsaether CM (2021)
Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI
Acta Oncol, 61 (1), 89-96
DOI 10.1080/0284186X.2021.1994645, PubMed 34783610

Guren MG, Sebag-Montefiore D, Franco P, Johnsson A, Segelov E, Deutsch E, Rao S, Spindler KG, Arnold D (2021)
Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Clin Colorectal Cancer, 20 (4), 279-287
DOI 10.1016/j.clcc.2021.09.006, PubMed 34645589

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Hjermstad MJ, Hamfjord J, Aass N, Dajani O, Lundeby T, Wester T, Kaasa S (2021)
Using Process Indicators to Monitor Documentation of Patient-Centred Variables in an Integrated Oncology and Palliative Care Pathway-Results from a Cluster Randomized Trial
Cancers (Basel), 13 (9)
DOI 10.3390/cancers13092194, PubMed 34063594

Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878

Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, Cillo U, Line PD (2021)
Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score
Transpl Int, 34 (9), 1722-1732
DOI 10.1111/tri.13981, PubMed 34448271

Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, Lund-Iversen M, Dagenborg VJ, Flatmark K, Sorbye H (2021)
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
Br J Cancer, 126 (5), 726-735
DOI 10.1038/s41416-021-01620-6, PubMed 34887523

Lundereng ED, Nes AAG, Holmen H, Winger A, Thygesen H, Jøranson N, Borge CR, Chen W, Dajani O, Mariussen KL, Steindal SA (2021)
Health Care Professionals' Experiences and Perspectives on Using Telehealth for Home-Based Palliative Care: Protocol for a Scoping Review
JMIR Res Protoc, 10 (10), e33305
DOI 10.2196/33305, PubMed 34714254

Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
Metastases in locally advanced rectal cancer undergoing curatively intended treatment
Eur J Surg Oncol, 47 (9), 2377-2383
DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768

Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
Br J Cancer, 125 (2), 240-246
DOI 10.1038/s41416-021-01377-y, PubMed 33837301

Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A (2021)
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Genome Med, 13 (1), 143
DOI 10.1186/s13073-021-00956-1, PubMed 34470666

Nilssen Y, Eriksen MT, Guren MG, Møller B (2021)
Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway
BMC Cancer, 21 (1), 757
DOI 10.1186/s12885-021-08415-1, PubMed 34187404

Osterman E, Ekström J, Sjöblom T, Kørner H, Myklebust TÅ, Guren MG, Glimelius B (2021)
Accurate population-based model for individual prediction of colon cancer recurrence
Acta Oncol, 60 (10), 1241-1249
DOI 10.1080/0284186X.2021.1953138, PubMed 34279175

Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, Guren MG, Tervonen H, Little A, O'Connell DL, Gavin A, De P, Thomsen LA, Moller B, Jackson C, Bucher O, Walsh PM, Vernon S, Bray F, Soerjomataram I (2021)
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. (vol 148, 1575, 2021)
Int. J. Cancer, 149 (6), E9
DOI 10.1002/ijc.33717

Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, Janson ET, Hansen CP, Ladekarl M, Garresori H, Hjortland GO, Sundlöv A, Galleberg R, Knigge P, Kjaer A, Langer SW, Knigge U (2021)
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
J Neuroendocrinol, 33 (5), e12967
DOI 10.1111/jne.12967, PubMed 33769624

Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, Deutsch E, Martinelli E, Arnold D, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021)
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆
Ann Oncol, 32 (9), 1087-1100
DOI 10.1016/j.annonc.2021.06.015, PubMed 34175386

REACCT Collaborative, Zaborowski AM, Abdile A, Adamina M, Aigner F, d'Allens L, Allmer C, Álvarez A, Anula R, Andric M, Atallah S, Bach S, Bala M, Barussaud M, Bausys A, Bebington B, Beggs A, Bellolio F, Bennett MR, Berdinskikh A, Bevan V, Biondo S, Bislenghi G, Bludau M, Boutall A et al. (2021)
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review
JAMA Surg, 156 (9), 865-874
DOI 10.1001/jamasurg.2021.2380, PubMed 34190968

Rønde HS, Kallehauge JF, Kronborg CJS, Nyvang L, Rekstad BL, Hanekamp BA, Appelt AL, Guren MG, Spindler KLS (2021)
Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation
Acta Oncol, 60 (11), 1436-1439
DOI 10.1080/0284186X.2021.1953139, PubMed 34264785

Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592

Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol, 28 (9), 5252-5262
DOI 10.1245/s10434-021-10022-0, PubMed 34019185

Torstveit AH, Løyland B, Grov EK, Guren M, Paul SM, Ritchie C, Vistad I, Miaskowski C, Utne I (2021)
Distinctions Between Self-Report and Performance-Based Measures of Physical Function in Older Patients Prior to Chemotherapy
Cancer Nurs, 44 (6), E735-E744
DOI 10.1097/NCC.0000000000000964, PubMed 34183518

Torstveit AH, Miaskowski C, Løyland B, Grov EK, Guren MG, Ritchie CS, Paul SM, Kleven AG, Utne I (2021)
Common and distinct characteristics associated with self-reported functional status in older patients with cancer receiving chemotherapy
Eur J Oncol Nurs, 54, 102033
DOI 10.1016/j.ejon.2021.102033, PubMed 34537538

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S (2021)
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 29 (1), 1-14
DOI 10.1530/ERC-21-0152, PubMed 34647903

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

Al-Haidari G, Skovlund E, Undseth C, Rekstad BL, Larsen SG, Åsli LM, Dueland S, Malinen E, Guren MG (2020)
Re-irradiation for recurrent rectal cancer - a single-center experience
Acta Oncol, 59 (5), 534-540
DOI 10.1080/0284186X.2020.1725111, PubMed 32056476

Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, Ferlay J, Tervonen H, Shack L, Woods RR, Saint-Jacques N, De P, McClure C, Engholm G, Gavin AT, Morgan E, Walsh PM, Jackson C, Porter G, Møller B, Bucher O, Eden M, O'Connell DL, Bray F, Soerjomataram I (2020)
Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)
Gut, 70 (1), 114-126
DOI 10.1136/gutjnl-2020-320625, PubMed 32482683

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, RAPIDO collaborative investigators (2020)
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Lancet Oncol, 22 (1), 29-42
DOI 10.1016/S1470-2045(20)30555-6, PubMed 33301740

Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056

Breugom AJ, Bastiaannet E, Guren MG, Kørner H, Boelens PG, Dekker FW, Kapiteijn E, Gelderblom H, Larsen IK, Liefers GJ, van de Velde CJH (2020)
Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
Eur J Surg Oncol, 46 (6), 1167-1173
DOI 10.1016/j.ejso.2020.02.005, PubMed 32151531

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813

Dahl O, Myklebust MP, Dale JE, Leon O, Serup-Hansen E, Jakobsen A, Pfeiffer P, Løes IM, Pfeffer F, Spindler KG, Guren MG, Glimelius B, Johnsson A (2020)
Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version
Acta Oncol, 59 (9), 1016-1023
DOI 10.1080/0284186X.2020.1778180, PubMed 32574087

Dueland S, Line PD (2020)
Response to the Comment on"Survival Following Liver Transplantation for Patients With Non-resectable Liver Only Colorectal Metastases": What if those Lesions Are Gone?
Ann Surg, 271 (5), e124
DOI 10.1097/SLA.0000000000003604, PubMed 32301798

Dueland S, Line PD (2020)
Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases
Hepatobiliary Surg Nutr, 9 (3), 382-384
DOI 10.21037/hbsn.2019.11.15, PubMed 32509836

Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, Vestermark LW, Ali AS, Zlobec I, Myklebust TÅ, Hjortland GO, Langer SW, Gronbaek H, Knigge U, Tiensuu Janson E, Sorbye H (2020)
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations
Neuroendocrinology, 111 (9), 883-894
DOI 10.1159/000511905, PubMed 33002892

Frydenberg H, Harsem NK, Ofigsbø Å, Skoglund H, Brændengen M, Kaasa S, Guren MG (2020)
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
Clin Colorectal Cancer, 19 (2), 141-144
DOI 10.1016/j.clcc.2020.02.013, PubMed 32222353

Isasi I, Irusta U, Aramendi E, Olsen JA, Wik L (2020)
Detection of Shockable Rhythms Using Convolutional Neural Networks During Chest Compressions Provided by a Load Distributing Band
COMPUT CARDIOL CONF, 45
DOI 10.22489/CinC.2020.045

Kværner AS, Harnæs H, Alavi DH, Bärebring L, Henriksen HB, Guren MG, Lauritzen PM, Eggesbø HB, Wiedswang G, Smeland S, Blomhoff R (2020)
Should calculation of chemotherapy dosage for bowel cancer be based on body composition?
Tidsskr Nor Laegeforen, 140 (8)
DOI 10.4045/tidsskr.19.0769, PubMed 32463187

Lanari J, Dueland S, Line PD (2020)
Liver Transplantation for Colorectal Liver Metastasis
Curr. Transplant. Rep., 7 (4), 311-316
DOI 10.1007/s40472-020-00298-8

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maingon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D (2020)
International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic
Radiother Oncol, 148, 213-215
DOI 10.1016/j.radonc.2020.03.039, PubMed 32342861

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2020)
Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
Transl Oncol, 13 (1), 122-124
DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135

Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Hjortland GO, Bartella I, Schröder W, Bruns C, Nilsson M (2020)
Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Ann Surg, 272 (5), 684-689
DOI 10.1097/SLA.0000000000004340, PubMed 32833767

Palmer DH, Valle JW, Ma YT, Faluyi O, Neoptolemos JP, Jensen Gjertsen T, Iversen B, Amund Eriksen J, Møller AS, Aksnes AK, Miller R, Dueland S (2020)
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
Br J Cancer, 122 (7), 971-977
DOI 10.1038/s41416-020-0752-7, PubMed 32063605

Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, Grønlie Guren M, Tervonen H, Little A, O'Connell DL, Gavin A, De P, Aagard Thomsen L, Møller B, Jackson C, Bucher O, Walsh PM, Vernon S, Bray F, Soerjomataram I (2020)
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study
Int J Cancer, 148 (7), 1575-1585
DOI 10.1002/ijc.33326, PubMed 33006395

Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D (2020)
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct
J Clin Oncol, 38 (22), 2510-2518
DOI 10.1200/JCO.19.03266, PubMed 32530769

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124

Thøgersen H, Møller B, Åsli LM, Bhargava S, Kvåle R, Fjellbirkeland L, Robsahm TE, Aaserud S, Babigumira R, Larsen IK (2020)
Waiting times and treatment following cancer diagnosis: comparison between immigrants and the Norwegian host population
Acta Oncol, 59 (4), 376-383
DOI 10.1080/0284186X.2019.1711167, PubMed 31920119

Publications 2019

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O, Engholm G, Jackson C, McClure C, Woods RR, Saint-Jacques N, Morgan E, Ransom D, Thursfield V, Møller B, Leonfellner S, Guren MG, Bray F, Arnold M (2019)
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Lancet Gastroenterol Hepatol, 4 (7), 511-518
DOI 10.1016/S2468-1253(19)30147-5, PubMed 31105047

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Ben-Aharon I, Goshen-Lago T, Fontana E, Smyth E, Guren M, Caballero C, Lordick F (2019)
Social networks for young patients with cancer: the time for system agility
Lancet Oncol, 20 (6), 765
DOI 10.1016/S1470-2045(19)30346-8, PubMed 31162090

Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ (2019)
Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
Pancreatology, 19 (2), 316-324
DOI 10.1016/j.pan.2019.01.019, PubMed 30713128

Brunsell TH, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A (2019)
Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
Eur J Surg Oncol, 45 (12), 2340-2346
DOI 10.1016/j.ejso.2019.07.017, PubMed 31350075

Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA (2019)
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Clin Colorectal Cancer, 19 (1), e26-e47
DOI 10.1016/j.clcc.2019.09.003, PubMed 31982351

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Guren MG (2019)
The global challenge of colorectal cancer
Lancet Gastroenterol Hepatol, 4 (12), 894-895
DOI 10.1016/S2468-1253(19)30329-2, PubMed 31648973

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Olsen JA, Brunborg C, Steinberg M, Persse D, Sterz F, Lozano M, Westfall M, van Grunsven PM, Lerner EB, Wik L (2019)
Survival to hospital discharge with biphasic fixed 360 joules versus 200 escalating to 360 joules defibrillation strategies in out-of-hospital cardiac arrest of presumed cardiac etiology
Resuscitation, 136, 112-118
DOI 10.1016/j.resuscitation.2019.01.020, PubMed 30708074

Rusten E, Rekstad BL, Undseth C, Klotz D, Hernes E, Guren MG, Malinen E (2019)
Anal cancer chemoradiotherapy outcome prediction using ¹⁸F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
Br J Radiol, 92 (1097), 20181006
DOI 10.1259/bjr.20181006, PubMed 30810343

Röhrl K, Guren MG, Astrup GL, Småstuen MC, Rustøen T (2019)
High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study
Eur J Oncol Nurs, 44, 101679
DOI 10.1016/j.ejon.2019.101679, PubMed 31751848

Röhrl K, Guren MG, Småstuen MC, Rustøen T (2019)
Symptoms during chemotherapy in colorectal cancer patients
Support Care Cancer, 27 (8), 3007-3017
DOI 10.1007/s00520-018-4598-y, PubMed 30607676

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA (2019)
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
ESMO Open, 4 (3), e000523
DOI 10.1136/esmoopen-2019-000523, PubMed 31321083

Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA (2019)
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
DOI 10.1038/s41389-019-0141-3, PubMed 31092812

Smedman TM, Guren TK, Line PD, Dueland S (2019)
Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study
Transpl Int, 32 (11), 1144-1150
DOI 10.1111/tri.13471, PubMed 31209941

Publications 2018

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET (2018)
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Med Oncol, 35 (4), 47
DOI 10.1007/s12032-018-1103-x, PubMed 29511910

Benitez Majano S, Di Girolamo C, Rachet B, Maringe C, Guren MG, Glimelius B, Iversen LH, Schnell EA, Lundqvist K, Christensen J, Morris M, Coleman MP, Walters S (2018)
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Lancet Oncol, 20 (1), 74-87
DOI 10.1016/S1470-2045(18)30646-6, PubMed 30545752

Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B, Sørbye H, Aas E (2018)
Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver
Br J Surg, 106 (1), 132-141
DOI 10.1002/bjs.10962, PubMed 30325494

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL (2018)
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
Clin Chim Acta, 487, 107-111
DOI 10.1016/j.cca.2018.09.029, PubMed 30240586

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA (2018)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
DOI 10.1002/1878-0261.12347, PubMed 29900672

Brændengen M, Glimelius B (2018)
Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers
Radiother Oncol, 127 (3), 392-395
DOI 10.1016/j.radonc.2018.05.004, PubMed 29778486

Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH (2018)
North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
Eur J Surg Oncol, 44 (12), 1982-1989
DOI 10.1016/j.ejso.2018.09.014, PubMed 30343998

Claassen YHM, Vermeer NCA, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Codina Cazador A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Rutten HJT, Portielje JEA, Liefers GJ, Holman FA, van de Velde CJH, Bastiaannet E (2018)
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison
Br J Cancer, 119 (4), 517-522
DOI 10.1038/s41416-018-0215-6, PubMed 30057408

Dueland S, Foss A, Solheim JM, Hagness M, Line PD (2018)
Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma
Br J Surg, 105 (6), 736-742
DOI 10.1002/bjs.10769, PubMed 29532908

Dueland S, Line PD, Hagness M, Foss A, Andersen MH (2018)
Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver
BJS Open, 3 (2), 180-185
DOI 10.1002/bjs5.50116, PubMed 30957065

Grut H, Revheim ME, Line PD, Dueland S (2018)
Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation
Nucl Med Commun, 39 (7), 621-627
DOI 10.1097/MNM.0000000000000843, PubMed 29683930

Guren MG, Aagnes B, Nygård M, Dahl O, Møller B (2018)
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016
Clin Colorectal Cancer, 18 (1), e96-e103
DOI 10.1016/j.clcc.2018.10.001, PubMed 30415990

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Line PD, Hagness M, Dueland S (2018)
The Potential Role of Liver Transplantation as a Treatment Option in Colorectal Liver Metastases
Can J Gastroenterol Hepatol, 2018, 8547940
DOI 10.1155/2018/8547940, PubMed 29623266

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA (2018)
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
DOI 10.1093/annonc/mdy085, PubMed 29518181

Smedman TM, Line PD, Guren TK, Dueland S (2018)
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Acta Oncol, 57 (10), 1414-1418
DOI 10.1080/0284186X.2018.1479069, PubMed 29912605

Steinberg MT, Olsen JA, Eriksen M, Neset A, Norseng PA, Kramer-Johansen J, Hardig BM, Wik L (2018)
Haemodynamic outcomes during piston-based mechanical CPR with or without active decompression in a porcine model of cardiac arrest
Scand J Trauma Resusc Emerg Med, 26 (1), 31
DOI 10.1186/s13049-018-0496-z, PubMed 29690910

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Vermeer NCA, Claassen YHM, Derks MGM, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Portielje JEA, Liefers GJ, Peeters KCMJ, van de Velde CJH, Bastiaannet E (2018)
Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison
Oncologist, 23 (8), 982-990
DOI 10.1634/theoncologist.2017-0551, PubMed 29567826

Publications 2017

Astrup GL, Hofsø K, Bjordal K, Guren MG, Vistad I, Cooper B, Miaskowski C, Rustøen T (2017)
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
Acta Oncol, 56 (3), 462-470
DOI 10.1080/0284186X.2016.1273546, PubMed 28077018

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Byskov CS, Nyvang L, Guren MG, Spindler KLG, Muren LP (2017)
The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer
Phys. Imag. Radiat. Oncol., 3, 43-48
DOI 10.1016/j.phro.2017.09.001

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017)
Acute liver graft rejection after ipilimumab therapy
Ann Oncol, 28 (10), 2619-2620
DOI 10.1093/annonc/mdx281, PubMed 28961840

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H (2017)
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Eur J Surg Oncol, 43 (9), 1682-1689
DOI 10.1016/j.ejso.2017.04.010, PubMed 28522174

Grut H, Dueland S, Line PD, Revheim ME (2017)
The prognostic value of ¹⁸F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases
Eur J Nucl Med Mol Imaging, 45 (2), 218-225
DOI 10.1007/s00259-017-3843-9, PubMed 29026950

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S (2017)
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases
Br J Surg, 105 (3), 295-301
DOI 10.1002/bjs.10651, PubMed 29168565

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA (2017)
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384

Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S (2017)
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial
BMC Surg, 17 (1), 94
DOI 10.1186/s12893-017-0291-1, PubMed 28841916

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Rusten E, Rekstad BL, Undseth C, Al-Haidari G, Hanekamp B, Hernes E, Hellebust TP, Malinen E, Guren MG (2017)
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205

Sodergren SC, Johnson CD, Gilbert A, Tomaszewski KA, Chu W, Chung HT, Dennis K, Desideri I, Glynne-Jones R, Grønlie Guren M, Kardamakis D, Nugent K, Schmidt H, Sebag-Montefiore D, Vassiliou V, EORTC Quality of Life Group (2017)
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Radiother Oncol, 126 (2), 222-228
DOI 10.1016/j.radonc.2017.11.018, PubMed 29217122

Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M (2017)
Quality of life as a prognostic factor for survival in hepatocellular carcinoma
Liver Int, 38 (5), 885-894
DOI 10.1111/liv.13593, PubMed 28941130

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH (2017)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Target Oncol, 12 (1), 97-109
DOI 10.1007/s11523-016-0469-y, PubMed 27975152

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG (2017)
Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study
Radiother Oncol, 123 (3), 446-453
DOI 10.1016/j.radonc.2017.04.012, PubMed 28483302

Publications 2016

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2016)
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
J Surg Oncol, 114 (2), 222-7
DOI 10.1002/jso.24290, PubMed 27173150

Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG (2016)
Two countries - Two treatment strategies for rectal cancer
Radiother Oncol, 121 (3), 357-363
DOI 10.1016/j.radonc.2016.11.010, PubMed 27887734

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat, 49 (2), 374-386
DOI 10.4143/crt.2016.080, PubMed 27488871

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458

Røhrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustøen T (2016)
No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy
J Pain Symptom Manage, 52 (4), 539-547
DOI 10.1016/j.jpainsymman.2016.04.008, PubMed 27470003

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Aamdal E (2016)
What is cancer exactly?
Tidsskr. Nor. Laegeforen., 136 (20), 1746
DOI 10.4045/tidsskr.16.0721

Publications 2015

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2015)
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575

Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA (2015)
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Clin Cancer Res, 21 (23), 5235-44
DOI 10.1158/1078-0432.CCR-15-0180, PubMed 26187616

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A (2015)
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970

Labori KJ, Schulz A, Drolsum A, Guren MG, Kløw NE, Bjørnbeth BA (2015)
Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center
Acta Radiol Open, 4 (7), 2058460115580877
DOI 10.1177/2058460115580877, PubMed 26346740

Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A (2015)
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer
Eur J Cancer, 51 (18), 2740-6
DOI 10.1016/j.ejca.2015.08.029, PubMed 26597443

Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S (2015)
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
Eur J Cancer, 51 (14), 1865-73
DOI 10.1016/j.ejca.2015.06.115, PubMed 26199039

Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, Peake M, Guren MG, Glimelius B, Bergström S, Påhlman L, Rachet B (2015)
Is England closing the international gap in cancer survival?
Br J Cancer, 113 (5), 848-60
DOI 10.1038/bjc.2015.265, PubMed 26241817

Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, Bye A (2015)
Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer
Nutr Cancer, 67 (3), 472-80
DOI 10.1080/01635581.2015.1004728, PubMed 25710201

Publications 2014

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, Naucler G, Svensson C, Tveit KM, Jakobsen A, Pfeiffer P, Wanderås E, Ekman T, Lindh B, Balteskard L, Frykholm G, Johnsson A (2014)
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Guren MG (2013)
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors
Acta Oncol, 52 (4), 736-44
DOI 10.3109/0284186X.2013.770599, PubMed 23438358

Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L (2013)
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort
Radiother Oncol, 108 (1), 55-60
DOI 10.1016/j.radonc.2013.05.037, PubMed 23891095

Braendengen M, Guren MG, Glimelius B (2013)
Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?
Curr. Colorectal Cancer Rep., 9 (2), 116-125
DOI 10.1007/s11888-013-0170-9

Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I (2013)
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801

Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG (2013)
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692

Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, Lothe RA (2013)
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914

Publications 2012

Amdal CD, Jacobsen AB, Guren MG, Bjordal K (2012)
Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review
Acta Oncol, 52 (4), 679-90
DOI 10.3109/0284186X.2012.731521, PubMed 23190360

Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L (2012)
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791

Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B (2012)
Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients
Acta Oncol, 52 (3), 528-37
DOI 10.3109/0284186X.2012.737022, PubMed 23113591

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2012)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
Ann Oncol, 24 (1), 152-60
DOI 10.1093/annonc/mds276, PubMed 22967994

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, Sandnes D, Christoffersen T (2012)
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
J Exp Clin Cancer Res, 31 (1), 72
DOI 10.1186/1756-9966-31-72, PubMed 22967907

Publications 2011

Brændengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B (2011)
Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study
Int J Radiat Oncol Biol Phys, 81 (4), e439-45
DOI 10.1016/j.ijrobp.2011.03.031, PubMed 21641122

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B (2011)
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Müller KM, Tveteraas IH, Aasrum M, Ødegård J, Dawood M, Dajani O, Christoffersen T, Sandnes DL (2011)
Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
BMC Cancer, 11, 421
DOI 10.1186/1471-2407-11-421, PubMed 21961726

Publications 2010

Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B (2010)
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Foss A, Adam R, Dueland S (2010)
Liver transplantation for colorectal liver metastases: revisiting the concept
Transpl Int, 23 (7), 679-85
DOI 10.1111/j.1432-2277.2010.01097.x, PubMed 20477993

Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
[How do Norwegian oncologists perceive their working conditions?]
Tidsskr Nor Laegeforen, 130 (5), 487-9
DOI 10.4045/tidsskr.08.0305, PubMed 20224615

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Publications 2009

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB (2009)
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer
J Clin Oncol, 27 (25), 4116-23
DOI 10.1200/JCO.2008.20.2515, PubMed 19636016

Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Tveit KM (2009)
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263

Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM (2009)
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058

Publications 2008

Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B (2008)
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG (2008)
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088

Larsen SG, Wiig JN, Emblemsvaag HL, Grøholt KK, Hole KH, Bentsen A, Dueland S, Vetrhus T, Giercksky KE (2008)
Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging
Colorectal Dis, 11 (7), 759-67
DOI 10.1111/j.1463-1318.2008.01649.x, PubMed 18662240

Ree AH, Bratland A, Dueland S (2008)
[Molecular targeted therapy in colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 190-3
PubMed 18202731

Sørbye H, Braendengen M, Balteskard L (2008)
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 194-7
PubMed 18202732

Publications 2007

Larsen SG, Wiig JN, Dueland S, Giercksky KE (2007)
Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer
Eur J Surg Oncol, 34 (4), 410-7
DOI 10.1016/j.ejso.2007.05.012, PubMed 17614249

Meisdalen K, Dajani OF, Christoffersen T, Sandnes D (2007)
Prostaglandins enhance epidermal growth factor-induced DNA synthesis in hepatocytes by stimulation of E prostanoid 3 and F prostanoid receptors
J Pharmacol Exp Ther, 322 (3), 1044-50
DOI 10.1124/jpet.107.121277, PubMed 17567965

Wiig JN, Dueland S, Larsen S, Giercksky KE (2007)
[Treatment of locally recurrent rectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3097-101
PubMed 18049503

Wiig JN, Larsen SG, Dueland S, Giercksky KE (2007)
Preoperative irradiation and surgery for local recurrence of rectal and rectosigmoid cancer. Prognostic factors with regard to survival and further local recurrence
Colorectal Dis, 10 (1), 48-57
DOI 10.1111/j.1463-1318.2007.01398.x, PubMed 18028472

Publications 2006

Guren MG, Tobiassen LB, Trygg KU, Drevon CA, Dueland S (2006)
Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer
Eur J Clin Nutr, 60 (1), 113-9
DOI 10.1038/sj.ejcn.1602274, PubMed 16205744

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345

Publications 2005

Guren MG, Eriksen MT, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM, Norwegian Rectal Cancer Group (2005)
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Sauer T, Guren MG, Noren T, Dueland S (2005)
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
Histopathology, 47 (6), 560-4
DOI 10.1111/j.1365-2559.2005.02252.x, PubMed 16324192

Publications 2004

Guren MG, Schneede J, Tveit KM, Ueland PM, Nexø E, Dueland S (2004)
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O (2004)
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765

Uzdensky AB, Juzeniene A, Kolpakova E, Hjortland GO, Juzenas P, Moan J (2004)
Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum
Biochem Biophys Res Commun, 322 (2), 452-7
DOI 10.1016/j.bbrc.2004.07.132, PubMed 15325251

Publications 2003

Dueland S, Guren MG, Olsen DR, Poulsen JP, Magne Tveit K (2003)
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients
Radiother Oncol, 68 (3), 249-53
DOI 10.1016/s0167-8140(03)00120-8, PubMed 13129632

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM (2003)
Epidermal growth factor receptor inhibition induces trichomegaly
Acta Oncol, 42 (4), 345-6
DOI 10.1080/02841860310006038, PubMed 12899508

Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM (2003)
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/s0959-8049(02)00741-4, PubMed 12628837

Wiig JN, Waehre H, Larsen SG, Braendengen M, Giercksky KE (2003)
Radical prostatectomy for locally advanced primary or recurrent rectal cancer
Eur J Surg Oncol, 29 (5), 455-8
DOI 10.1016/s0748-7983(03)00030-1, PubMed 12798751

Publications 2002

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Melien O, Nilssen LS, Dajani OF, Sand KL, Iversen JG, Sandnes DL, Christoffersen T (2002)
Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases
BMC Cell Biol, 3, 5
DOI 10.1186/1471-2121-3-5, PubMed 11914123

Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE (2002)
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer
Eur J Surg, 168 (1), 42-8
DOI 10.1080/110241502317307562, PubMed 12022371

Publications 2001

Dueland S, Wist E, Løberg M, Iversen J (2001)
Cutaneous relapse of testicular embryonic carcinoma
J Urol, 165 (3), 909
DOI 10.1016/S0022-5347(05)66565-2, PubMed 11176507

Guren MG, Wiig JN, Dueland S, Tveit KM, Fosså SD, Waehre H, Giercksky KE (2001)
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593

Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J (2001)
Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines
Lasers Med Sci, 16 (4), 276-83
DOI 10.1007/pl00011364, PubMed 11702633

Publications 2000

Spitsen GM, Dueland S, Krisans SK, Slattery CJ, Miyake JH, Davis RA (2000)
In nonhepatic cells, cholesterol 7alpha-hydroxylase induces the expression of genes regulating cholesterol biosynthesis, efflux, and homeostasis
J Lipid Res, 41 (8), 1347-55
PubMed 10946023

Publications 1999

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165

Sandnes D, Dajani O, Bjørneby A, Christoffersen T (1999)
The relationship between activation of phosphoinositide-specific phospholipase C and growth stimulation by Ca2+-mobilizing hormones in hepatocytes
Pharmacol Toxicol, 84 (5), 234-40
DOI 10.1111/j.1600-0773.1999.tb01488.x, PubMed 10361980

Publications 1998

Dueland S, Stenwig AE, Heilo A, Høie J, Ous S, Fosså SD (1998)
Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94
Br J Cancer, 77 (2), 329-35
DOI 10.1038/bjc.1998.51, PubMed 9461006

Publications 1996

Braendengen M, Winderen M, Fosså SD (1996)
Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer
Br J Urol, 77 (1), 36-40
DOI 10.1046/j.1464-410x.1996.08467.x, PubMed 8653315

Guren TK, Thoresen GH, Dajani OF, Taraldsrud E, Moberg ER, Christoffersen T (1996)
Epidermal growth factor behaves as a partial agonist in hepatocytes: effects on DNA synthesis in primary culture and competition with transforming growth factor alpha
Growth Factors, 13 (3-4), 171-9
DOI 10.3109/08977199609003219, PubMed 8919025

Trawick JD, Lewis KD, Dueland S, Moore GL, Simon FR, Davis RA (1996)
Rat hepatoma L35 cells, a liver-differentiated cell line, display resistance to bile acid repression of cholesterol 7 alpha-hydroxylase
J Lipid Res, 37 (3), 588-98
PubMed 8728321

Publications 1995

Refsnes M, Dajani OF, Sandnes D, Thoresen GH, Røttingen JA, Iversen JG, Christoffersen T (1995)
On the mechanisms of the growth-promoting effect of prostaglandins in hepatocytes: the relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide-specific phospholipase C
J Cell Physiol, 164 (3), 465-73
DOI 10.1002/jcp.1041640304, PubMed 7650056

Thoresen GH, Refsnes M, Dajani OF, Johansen EJ, Christoffersen T (1995)
Dexamethasone inversely regulates DNA synthesis and phosphoenolpyruvate carboxykinase mRNA levels in cultured rat hepatocytes: interactions with insulin, glucagon, and transforming growth factor beta 1
Pharmacol Toxicol, 76 (3), 163-70
DOI 10.1111/j.1600-0773.1995.tb00124.x, PubMed 7617540

Publications 1994

Refsnes M, Thoresen GH, Dajani OF, Christoffersen T (1994)
Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor
J Cell Physiol, 159 (1), 35-40
DOI 10.1002/jcp.1041590106, PubMed 8138589

Publications 1992

Refsnes M, Thoresen GH, Sandnes D, Dajani OF, Dajani L, Christoffersen T (1992)
Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: role of alpha 1- and beta-adrenergic mechanisms
J Cell Physiol, 151 (1), 164-71
DOI 10.1002/jcp.1041510121, PubMed 1313818

Thrift RN, Drisko J, Dueland S, Trawick JD, Davis RA (1992)
Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in a nonhepatic cell line
Proc Natl Acad Sci U S A, 89 (19), 9161-5
DOI 10.1073/pnas.89.19.9161, PubMed 1409618

Publications 1991

Leighton JK, Dueland S, Straka MS, Trawick J, Davis RA (1991)
Activation of the silent endogenous cholesterol-7-alpha-hydroxylase gene in rat hepatoma cells: a new complementation group having resistance to 25-hydroxycholesterol
Mol Cell Biol, 11 (4), 2049-56
DOI 10.1128/mcb.11.4.2049-2056.1991, PubMed 2005896

Publications 1990

Straka MS, Junker LH, Zacarro L, Zogg DL, Dueland S, Everson GT, Davis RA (1990)
Substrate stimulation of 7 alpha-hydroxylase, an enzyme located in the cholesterol-poor endoplasmic reticulum
J Biol Chem, 265 (13), 7145-9
PubMed 2332427

Thoresen GH, Sand TE, Refsnes M, Dajani OF, Guren TK, Gladhaug IP, Killi A, Christoffersen T (1990)
Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry
J Cell Physiol, 144 (3), 523-30
DOI 10.1002/jcp.1041440321, PubMed 2167904

Publications 1985

Albrechtsen D, Helgerud P, Rugstad HE, Dueland S (1985)
Very high concentration in intestinal lymph after oral, but not after intravenous, cyclosporine in the rat
Transplantation, 40 (2), 220-2
DOI 10.1097/00007890-198508000-00025, PubMed 4024244

Dueland S, Bouillon R, Van Baelen H, Pedersen JI, Helgerud P, Drevon CA (1985)
Binding protein for vitamin D and its metabolites in rat mesenteric lymph
Am J Physiol, 249 (1 Pt 1), E1-5
DOI 10.1152/ajpendo.1985.249.1.E1, PubMed 2990230

Publications 1984

Blomhoff R, Helgerud P, Dueland S, Berg T, Pedersen JI, Norum KR, Drevon CA (1984)
Lymphatic absorption and transport of retinol and vitamin D-3 from rat intestine. Evidence for different pathways
Biochim Biophys Acta, 772 (2), 109-16
DOI 10.1016/0005-2736(84)90033-6, PubMed 6326820

Publications 1983

Dueland S, Helgerud P, Pedersen JI, Berg T, Drevon CA (1983)
Plasma clearance, transfer, and distribution of vitamin D3 from intestinal lymph
Am J Physiol, 245 (4), E326-31
DOI 10.1152/ajpendo.1983.245.4.E326, PubMed 6312805

Dueland S, Pedersen JI, Helgerud P, Drevon CA (1983)
Absorption, distribution, and transport of vitamin D3 and 25-hydroxyvitamin D3 in the rat
Am J Physiol, 245 (5 Pt 1), E463-7
DOI 10.1152/ajpendo.1983.245.5.E463, PubMed 6314821

Publications 1982

Davis RA, Helgerud P, Dueland S, Drevon CA (1982)
Evidence that reverse cholesterol transport occurs in vivo and requires lecithin-cholesterol acyltransferase
Biochim Biophys Acta, 689 (2), 410-4
DOI 10.1016/0005-2736(82)90276-0, PubMed 7115718

Dueland S, Pedersen JI, Drevon CA, Björkhem I (1982)
26-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol by isolated nonparenchymal cells and hepatocytes from rat liver
J Lipid Res, 23 (9), 1321-7
PubMed 7161561

Dueland S, Pedersen JI, Helgerud P, Drevon CA (1982)
Transport of vitamin D3 from rat intestine. Evidence for transfer of vitamin D3 from chylomicrons to alpha-globulins
J Biol Chem, 257 (1), 146-50
PubMed 6171567

Hansen CE, Dueland S, Drevon CA, Størmer FC (1982)
Metabolism of ochratoxin A by primary cultures of rat hepatocytes
Appl Environ Microbiol, 43 (6), 1267-71
DOI 10.1128/aem.43.6.1267-1271.1982, PubMed 7103484

Publications 1981

Dueland S, Holmberg I, Berg T, Pedersen JI (1981)
Uptake and 25-hydroxylation of vitamin D3 by isolated rat liver cells
J Biol Chem, 256 (20), 10430-4
PubMed 6270111

DUELAND S, HOLMBERG I, BERG T, PEDERSEN JI (1981)
UPTAKE AND 25-HYDROXYLATION OF VITAMIN-D3 BY ISOLATED RAT-LIVER CELLS
J. Biol. Chem., 256 (20), 430-434